Chronic idiopathic constipation (CIC) is a health condition in which a person experiences chronic symptoms of constipation, yet no visible cause can be identified through standard diagnostic testing. The term idiopathic is used because it means there is no known cause. CIC includes symptoms of difficult, infrequent, or incomplete bowel movements.

The global Chronic Idiopathic Constipation (CIC) Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Chronic Idiopathic Constipation (CIC) Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Chronic Idiopathic Constipation (CIC) Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Chronic Idiopathic Constipation (CIC) Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Chronic Idiopathic Constipation (CIC) Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Actavis
Chugai Pharmaceutical
Ferring International Center
Synergy Pharmaceuticals
Pfizer
GlaxoSmithKline
Roche Holding
Sanofi
Bayer
Salix Pharmaceuticals
Sucampo Pharmaceuticals
Ironwood Pharmaceuticals
Progenics Pharmaceuticals

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Lubiprostone
Linaclotide
Others

Segment by Application
Hospitals & Clinics
Ambulatory Surgical Centres
Long Term Care Centres
Others